
1. lancet infect dis. 2020 jul 14. pii: s1473-3099(20)30228-0. doi:
10.1016/s1473-3099(20)30228-0. [epub ahead print]

molecular epidemiology resistance antimalarial drugs greater mekong 
subregion: observational study.

imwong m(1), dhorda m(2), myo tun k(3), thu am(4), phyo ap(5), proux s(4),
suwannasin k(6), kunasol c(6), srisutham s(6), duanguppama j(6), vongpromek r(7),
promnarate c(7), saejeng a(8), khantikul n(9), sugaram r(8), thanapongpichat
s(10), sawangjaroen n(11), sutawong k(12), han kt(13), htut y(13), linn k(13),
win aa(14), hlaing tm(15), van der pluijm rw(16), mayxay m(17), pongvongsa t(18),
phommasone k(19), tripura r(16), peto tj(16), von seidlein l(16), nguon c(20),
lek d(20), chan xhs(16), rekol h(20), leang r(20), huch c(20), kwiatkowski
dp(21), miotto o(22), ashley ea(23), kyaw mp(24), pukrittayakamee s(25), day
npj(16), dondorp am(16), smithuis fm(26), nosten fh(27), white nj(16).

author information: 
(1)department molecular tropical medicine genetics, faculty tropical
medicine, mahidol university, bangkok, thailand; mahidol-oxford tropical medicine
research unit, faculty tropical medicine, mahidol university, bangkok,
thailand. electronic address: mallika.imw@mahidol.ac.th.
(2)mahidol-oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand; worldwide antimalarial resistance network,
bangkok, thailand.
(3)department preventive social medicine, defence services medical
academy, yangon, myanmar.
(4)shoklo malaria research unit, mahidol-oxford tropical medicine research unit, 
faculty tropical medicine, mahidol university, mae sot, thailand.
(5)shoklo malaria research unit, mahidol-oxford tropical medicine research unit, 
faculty tropical medicine, mahidol university, mae sot, thailand; myanmar
oxford clinical research unit, yangon, myanmar.
(6)mahidol-oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand.
(7)worldwide antimalarial resistance network, bangkok, thailand.
(8)bureau vector-borne diseases, department disease control, ministry of
public health, nonthaburi, thailand.
(9)office disease prevention control region 1, chiang mai, thailand.
(10)faculty medical technology, prince songkla university, songkhla,
thailand.
(11)department microbiology, faculty science, prince songkla university,
songkhla, thailand.
(12)buntharik hospital, amphoe buntharik, ubon ratchathani, thailand.
(13)department medical research, ministry health sports, yangon,
myanmar.
(14)department tropical infectious diseases, university medicine 1,
yangon, myanmar.
(15)defence services medical research centre, naypyitaw, myanmar.
(16)mahidol-oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; centre tropical medicine global
health, nuffield department medicine, university oxford, oxford, uk.
(17)institute research education development, university health
sciences, ministry health, vientiane, laos; lao-oxford-mahosot
hospital-wellcome trust research unit, vientiane, laos.
(18)savannakhet provincial health department, phonsavangnuea village,
kaysone-phomvihan district, savannakhet, laos.
(19)lao-oxford-mahosot hospital-wellcome trust research unit, vientiane, laos.
(20)national center parasitology, entomology, malaria control, phnom
penh, cambodia.
(21)wellcome sanger institute, hinxton, uk; medical research council centre for
genomics global health, big data institute, university oxford, oxford, uk.
(22)mahidol-oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; wellcome sanger institute, hinxton, uk;
medical research council centre genomics global health, big data
institute, university oxford, oxford, uk.
(23)centre tropical medicine global health, nuffield department of
medicine, university oxford, oxford, uk; lao-oxford-mahosot hospital-wellcome 
trust research unit, vientiane, laos.
(24)department medical research, myanmar health network organization, yangon, 
myanmar.
(25)mahidol-oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; department clinical tropical medicine, 
faculty tropical medicine, mahidol university, bangkok, thailand; royal
society thailand, dusit, bangkok, thailand.
(26)myanmar oxford clinical research unit, yangon, myanmar; centre tropical
medicine global health, nuffield department medicine, university of
oxford, oxford, uk; medical action myanmar, yangon, myanmar.
(27)shoklo malaria research unit, mahidol-oxford tropical medicine research unit,
faculty tropical medicine, mahidol university, mae sot, thailand; centre for
tropical medicine global health, nuffield department medicine, university 
of oxford, oxford, uk.

background: greater mekong subregion recurrent source antimalarial
drug resistance plasmodium falciparum malaria. study aimed to
characterise extent spread resistance across entire region
between 2007 2018.
methods: p falciparum isolates myanmar, thailand, laos, cambodia were
obtained clinical trials epidemiological studies done jan 1,
2007, dec 31, 2018, genotyped molecular markers (pfkelch, pfcrt,
pfplasmepsin2, pfmdr1) antimalarial drug resistance. genetic relatedness
was assessed using microsatellite single nucleotide polymorphism typing of
flanking sequences around target genes.
findings: 10 632 isolates genotyped. single long pfkelch cys580tyr
haplotype (from -50 kb +31·5 kb) conferring artemisinin resistance (pfpailin) 
now dominates across eastern greater mekong subregion. piperaquine resistance
associated pfplasmepsin2 gene amplification mutations pfcrt
downstream lys76thr chloroquine resistance locus also developed. on
the thailand-myanmar border different pfkelch cys580tyr lineage rose high
frequencies eliminated. elsewhere myanmar cys580tyr allele
remains widespread low allele frequencies. meanwhile single
artemisinin-resistant pfkelch phe446ile haplotype spread across myanmar.
despite intense use dihydroartemisinin-piperaquine kayin state, eastern
myanmar, treatment mass drug administrations, selection of
piperaquine resistance markers observed. pfmdr1 amplification, marker of
resistance mefloquine, remains low prevalence across entire region.
interpretation: artemisinin resistance p falciparum prevalent across
the greater mekong subregion. eastern greater mekong subregion multidrug
resistant p falciparum lineage (pfpailin) dominates. myanmar long pfkelch
phe446ile haplotype spread widely but, contrast eastern greater
mekong subregion, indication artemisinin combination therapy (act)
partner drug resistance genotyping known markers, evidence spread 
of act resistant p falciparum east west. still window 
of opportunity prevent global spread act resistance.
funding: thailand science research innovation, initiative 5%, expertise
france, wellcome trust.

copyright © 2020 author(s). published elsevier ltd. open access
article cc 4.0 license. published elsevier ltd.. rights
reserved.

doi: 10.1016/s1473-3099(20)30228-0 
pmid: 32679084 

